A5022515199- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CAR-T cell therapy research
- Virus-based gene therapy research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- RNA Interference and Gene Delivery
- Neutropenia and Cancer Infections
- Cancer Treatment and Pharmacology
- Biosimilars and Bioanalytical Methods
- Chemokine receptors and signaling
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- CRISPR and Genetic Engineering
- CNS Lymphoma Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Chemotherapy-related skin toxicity
- Monoclonal and Polyclonal Antibodies Research
- Viral Infectious Diseases and Gene Expression in Insects
- Gastrointestinal Tumor Research and Treatment
- Click Chemistry and Applications
Klinikum Saarbrücken
2023-2024
Klinikum Osnabrück
2011-2024
Allegheny Health Network
2019
Cancer Institute (WIA)
2019
Center for HIV and Hepatogastroenterology
2014
Paracelsus-Kliniken
2009-2011
Heidelberg University
2001-2009
Zero to Three
2007
German Cancer Research Center
2001
Despite the clinical application of adeno-associated virus (AAV) gene therapy, titration viral stocks has not yet been standardized. This complicates comparison between laboratories. Functional titering AAV is time-consuming, requires manipulation hazardous material, and often a high degree variability. We established an optimized real-time quantitative polymerase chain reaction (RQ-PCR) assay to determine titers compared it with functional green fluorescent protein (GFP)-based method. With...
Abstract BACKGROUND Despite advances in drug therapy and allogeneic stem cell transplantation (allo‐SCT), the prognosis of patients with chronic myeloid leukemia (CML) blast crisis remains poor. Imatinib has demonstrated synergistic effects vitro mitoxantrone, etoposide, cytarabine. METHODS A Phase I/II trial was performed CML crisis. Patients were treated imatinib + mitoxantrone/etoposide four cohorts: mitoxantrone 10 mg/m 2 /day etoposide 100 for or 3 consecutive days 600 mg/day from Day...
Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level CD20-expression in B-cell chronic lymphocytic (B-CLL) low comparison other lymphomas normal B-cells. Previous experience rituximab small series B-CLL suggest it less than follicular lymphomas. We analyzed correlation between efficacy eight refractory or relapsed two prolymphocytic (B-PLL). could...
The tyrosine kinase activity of the BCR-ABL oncoprotein results in reduced apoptosis and thus prolongs survival chronic myelogenous leukaemia cells. inhibitor imatinib (formerly STI571) was reported to selectively suppress proliferation BCR-ABL-positive Assuming that could be included pretransplantation conditioning therapies, we tested whether combinations gamma-irradiation or alkylating agents such as busulfan treosulfan would display synergistic BV173 EM-3 cell lines. Further, primary...
Peripheral blood progenitor cells (PBPC) can be mobilized using chemotherapy and granulocyte colony‐stimulating factor (G‐CSF). We others previously reported a correlation of steady‐state PBPC counts the yield during mobilization in small group patients. Here we present data on 100 patients (patients: 25 non‐Hodgkin's lymphoma (NHL), five Hodgkin's disease, 35 multiple myeloma (MM), solid tumour) which enabled detailed analysis determinants levels efficiency patient subgroups. Previous...
Abstract Hematopoietic cells extend multiple podia of yet unknown function. Our morphological studies using scanning electron microscopy and functional time-lapse video suggest that formed by CD34+ hematopoietic stem (HSC) on the bone marrow stroma component fibronectin are characteristic lamellipodia at leading edge uropodia trailing edge, cytoskeletal structures have previously been shown to be responsible for cell locomotion lymphocytes. In leukemic studied here, stroma-derived factor-1α...
Abstract Chronic myelogenous leukemia (CML) is characterized by aberrant trafficking of malignant hematopoietic progenitor cells in the peripheral blood. Expression cell adhesion molecule CD62L was reported to be significantly lower CML patients than normal controls. We studied whether transcription dependent on activity BCR-ABL tyrosine kinase. Following addition Abelson (ABL) kinase inhibitor imatinib (formerly STI571) two BCR-ABL-positive lines (BV173, SD-1), we observed a dose-dependent...
Methods to analyze the clonality of an adverse event in preclinical or clinical retroviral stem cell gene therapy protocols are needed. We analyzed progeny retrovirally transduced human peripheral blood progenitor cells (PBPCs) after transplantation and engraftment immune‐deficient mice. The integration site provirus serves as a unique tag individual PBPC. A plasmid library junctions between proviral genomic DNA was generated. were able detect clones that amounted 0.14%–0.0001% chimeric bone...
Gene transfer into chronic myelogenous leukemia (CML) cells may become of relevance for overcoming therapy resistance. Single-stranded pseudotyped adeno-associated viruses serotypes 2/1 to 2/6 (ssAAV2/1–ssAAV2/6) were screened on human CML cell lines and primary determine gene efficiency. Additionally, double-stranded self-complementary vectors (dsAAVs) used possible second-strand synthesis limitations. On lines, ssAAV2/2 ssAAV2/6 most efficient. cells, proved significantly more efficient...
Abstract Health-related quality of life (HRQoL) data are important indicators health status in patients with lymphoma. The objective this analysis was to assess the impact treatment Sandoz rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on HRQoL treatment-naïve adult diffuse large B-cell lymphoma (DLBCL) included prospective, real-world REFLECT study. is first prospective study DLBCL treated a biosimilar. assessed via patient-reported European Organization...